Novavax Inc

Most Recent

  • Novavax scientist working on COVID-19 vaccine
    Healthcare

    Novavax Vaccine Is Spearheaded by Institutional Investors

    By Rachel Curry
  • Novavax vaccine being scanned in laboratory
    Healthcare

    Novavax Combined Vaccine Explained, NVAX Stock Looks Iffy

    By Rachel Curry
  • What is the Novavax Vaccine, and How NVAX Stock Reacted to Updates?
    Healthcare

    Novavax Inches Closer to COVID-19 Vaccine, Stock Reacts to Updates

    By Ambrish Shah
  • Is Novavax NVAX Stock a Buy or Sell?
    Healthcare

    Is Novavax Stock a Good Buy at This Price?

    By Ambrish Shah
  • will novavax stock rally covid
    Healthcare

    Novavax Stock Jumps Due to COVID-19 Vaccine Trial Results

    By Ruchi Gupta
  • uploads///laboratory _
    Healthcare

    Pfizer Soars Due to Hopes about a Coronavirus Vaccine

    Pfizer (NYSE:PFE) stock rose 2.4% in pre-market trading at 7:51 AM ET today. The company’s experimental COVID-19 vaccine showed positive results.

    By Ambrish Shah
  • uploads///ferry _
    Consumer

    Can You Still Get a Piece of Norwegian Cruise Line Stock?

    Today at 6:22 AM ET, Norwegian Cruise Line Holdings (NASDAQ:NCLH) stock rose 12% to $17.90 in the pre-market session. What can investors expect?

    By Ambrish Shah
  • uploads///cruise _
    Consumer

    Buy Carnival Stock before It Makes Another Big Move

    Today at 6:32 AM ET, Carnival (NYSE:CCL) stock rose 11% to $16.00 in the pre-market session. The company has been benefiting from positive developments.

    By Ambrish Shah
  • uploads///coronavirus _
    Healthcare

    Novavax Soared 20% on Coronavirus Vaccine Hopes

    Today at 4:37 AM ET, Novavax stock rose 20% to $55.40 in the pre-market session. The company started the Phase I study of NVX-CoV2373.

    By Ambrish Shah
  • uploads///marijuana covid
    Cannabis

    Could Certain Marijuana Strains Help Fight COVID-19?

    The cannabis industry is doing its own research amid COVID-19. Researchers discovered that marijuana might have properties to fight the coronavirus.

    By Sushree Mohanty
  • uploads///ferry boat _
    Consumer

    Is Carnival Stock Worth Your Attention Right Now?

    Carnival stock rose 15.2% on Monday and closed at $14.72 with a market cap of $10.7 billion. The stock price rose due to hope about a COVID-19 vaccine.

    By Ambrish Shah
  • uploads///laboratory _
    Healthcare

    Coronavirus Vaccine: Novavax and Moderna Lead the Race

    Novavax stock rose almost 133% in the week ended May 15 and closed at $43.63. The stock has generated returns of 552% in the last 12 months.

    By Ambrish Shah
  • uploads///vaccine _
    Healthcare

    Novavax Rose 38% Due to $384 Million COVID-19 Funding

    Today at 4:30 AM ET, Novavax stock rose 38% to $33.74 in the pre-market session. The company received funding for its COVID-19 vaccine candidate.

    By Ambrish Shah
  • uploads///Graph
    Earnings Report

    NanoFlu Vaccine Could Be Big Growth Opportunity for Novavax

    On January 3, Novavax (NVAX) issued a press release announcing positive results from a Phase 2 trial that compared multiple quadrivalent formulations of its Nanoflu vaccine.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Will the ResVax Vaccine Be Key Revenue Driver for Novavax?

    On February 28, Novavax (NVAX) issued a press release announcing results from the first-ever Phase 3 trial for PrepareTM.

    By Margaret Patrick
  • uploads///syringe _
    Earnings Report

    What Analysts Are Recommending for Novavax after Q1 Results

    Novavax (NVAX) reported first-quarter results on May 2.

    By Margaret Patrick
  • uploads///businessman _
    Company & Industry Overviews

    Why Novavax Is Tanking Today

    Today, Novavax (NVAX) is trading close to $0.70, which is about 67.13% lower than its previous closing price.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amarin or Novavax: Who’s Controlling Expenses Better?

    In its investor presentation, Amarin (AMRN) highlighted the United States as its priority target market for commercializing Vascepa.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amarin or Novavax: Which Will Report Faster EPS Growth?

    In its investor presentation, Amarin (AMRN) highlighted the annual death toll attributable to cardiovascular disease in the United States to more than 800,000 while the yearly treatment cost is estimated at $555 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Amarin or Novavax: Which Will Report Faster Revenue Growth?

    With its 2018 unaudited results, as announced in an investor presentation, Amarin (AMRN) has guided for net total revenue in the range of $72 million–$76 million…

    By Margaret Patrick
  • uploads///fish oil _
    Company & Industry Overviews

    What Wall Street Recommends for Amarin and Novavax

    On February 22, Amarin (AMRN) closed at $19.87, 14% higher than its previous closing price and 746% higher than its 52-week low of $2.35.

    By Margaret Patrick
  • uploads///syringe _
    Company & Industry Overviews

    Novavax Rose Due to Positive NanoFlu Vaccine Results

    On January 3, Novavax (NVAX) issued a press release announcing positive top-line results from NanoFlu vaccine Phase 2 trial.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novavax’s ResVax Vaccine Could Be Blockbuster Market Opportunity

    Novavax expects the peak revenue opportunity for its ResVax maternal immunization vaccine to be ~$750 million in the United States.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ResVax Vaccine Program Is Novavax’s Key Growth Driver in 2018

    Novavax (NVAX) completed enrollment of its ResVax infant vaccine program through maternal immunization in the second quarter of 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novavax Expected to Report Solid Revenue Growth in Fiscal 2018

    Wall Street analysts expect Novavax to report revenues of $36.36 million in fiscal 2018, which is a YoY (year-over-year) rise of 21.86%.

    By Margaret Patrick
  • uploads///syringe _
    Company & Industry Overviews

    Gauging Analysts’ Expectations for Novavax and Peers in August

    Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation, which is the current source of its revenue.

    By Kenneth Smith
  • uploads///NVAX
    Company & Industry Overviews

    Why Novavax Sees a Huge Opportunity in Its Influenza Vaccine

    Novavax (NVAX) expects the seasonal influenza vaccine market in the world’s top seven markets to grow from ~$3.2 billion in the 2012–2013 season to $5.3 billion by the 2021–2022 season.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    How Much Upside Analysts See In Novavax Stock

    Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing recombinant nanoparticle vaccines and adjuvants to market.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    How Analysts View Agios Pharmaceuticals and Peers in March 2018

    Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one gave it a “strong buy” rating, and six gave it a “buy” rating.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Analysts’ Ratings for Sorrento and Its Peers in March 2018

    Of the two analysts covering Sorrento Therapeutics in March 2018, one analyst has given it a “strong buy” recommendation.

    By Kenneth Smith
  • uploads///virus _
    Company & Industry Overviews

    What Analysts Recommend for AbbVie and Peers in March 2018

    Of the 23 analysts covering AbbVie in March 2018, four analysts have given the stock a “strong buy,” six have given it a “buy,” 12 have given it a “hold,” and one has given it a “sell.”

    By Kenneth Smith
  • uploads///OMER
    Company & Industry Overviews

    What’s behind Omeros’s Cash Flow

    In fiscal 2017, Omeros spent $36.2 million on operating activities, compared with $51.5 million in fiscal 2016.

    By Kenneth Smith
  • uploads///virus _
    Company & Industry Overviews

    Analysts’ Ratings for Omeros and Peers in March 2018

    Omeros (OMER) is a commercial biopharmaceutical company. Its product, Omidria, is used in cataract surgery.

    By Kenneth Smith
  • uploads///XNCR
    Company & Industry Overviews

    Exploring Xencor’s Cash Flows

    Xencor (XNCR) used $33.6 million in operating activities in 2017. In 2016, the company generated $94.6 million from operating activities.

    By Kenneth Smith
  • uploads///pill _
    Company & Industry Overviews

    Analysts’ Recommendations for Xencor and Its Peers in March

    Of the six analysts covering Xencor in March 2018, three have given the stock “strong buy” ratings.

    By Kenneth Smith
  • uploads///NVAX
    Company & Industry Overviews

    A Strong Product Pipeline Bodes Well for Novavax

    Novavax’s nanoparticle influenza vaccine (or NanoFlu) is currently in Phase 1 and Phase 2 development.

    By Kenneth Smith
  • uploads///NVAX
    Company & Industry Overviews

    Analyzing Novavax’s Cash Flows

    Novavax generated $64.5 million from financing activities in fiscal 2017 compared with $279.0 million in fiscal 2016.

    By Kenneth Smith
  • uploads///Novavax Revenue Growth
    Company & Industry Overviews

    Chart in Focus: Novavax’s Financial Position in 2017

    Novavax (NVAX) generated revenues of $8.4 million in 3Q17 compared with $3.2 million in 3Q16.

    By Kenneth Smith
  • uploads///Novavax Ebola Zika and Influenza Pipeline
    Company & Industry Overviews

    An Overview of Novavax’s Influenza and Ebola Vaccines

    According to Novavax (NVAX), the value of the influenza vaccine market in developed markets is expected to reach $5.3 billion by 2021–2022 compared with $3.2 billion in 2012–2013.

    By Kenneth Smith
  • uploads///Novavax RSV Pipeline
    Company & Industry Overviews

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

    By Kenneth Smith
  • uploads///Novavax Analysts recommendations
    Company & Industry Overviews

    Inside Analysts’ Recommendations for Novavax in November 2017

    A clinical-stage biotech company, Novavax’s (NVAX) pipeline includes products for influenza, Ebola virus, and Zika virus. In November, two of seven analysts gave NVAX stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///Chart  Segment
    Company & Industry Overviews

    How Are Eli Lilly’s Business Segments Performing?

    Eli Lilly and Co.’s (LLY) overall business is classified into two business segments—Human Pharmaceuticals and Animal Health.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Bristol-Myers Squibb’s 2Q16 Estimates: Expect Growth!

    Bristol-Myers Squibb (BMY) is expected to report revenue growth of over 11% to $4.7 billion in its 2Q16 results on July 28, 2016.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI’s Holdings: What’s the Trend in Its Moving Averages?

    On June 15, 2016, XBI closed at $54.74. It was trading above its 20-day and 50-day moving averages. XBI’s 20-day moving average is $56.30.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Incyte Continues Its Growth Spree in 2015

    Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.

    By Mike Benson
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    XBI Rises in Contrast to a Flat Market

    XBI closed at $68.65 on November 17, 2015. Out of XBI’s 101 holdings, 70 stocks ended with positive returns, while 31 stocks ended in the red.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Kite Led Top Ten Stocks by Weight in XBI’s Biotechnology Subgroup

    Kite Pharma (KITE), which has a weight of 1.17% in the SPDR S&P Biotechnology ETF (XBI), rose 21.94% for the week ended September 11.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Benchmark Indexes Continue to Outperform IBB and XBI

    The iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) provide investors with an opportunity to hold a basket of stocks from different subindustries from the biotech sector.

    By Peter Neil
  • uploads///gks
    Earnings Report

    How Does Novavax Compare to Its Competitors?

    Novavax posted a negative EPS (earnings per share) of -$0.39 in 2Q15, which is better than its 1Q15 EPS.

    By Gabriel Kane
  • uploads///gks
    Earnings Report

    How Did Novavax Perform in 2Q15?

    Novavax (NVAX) posted a variety of positive qualitative and quantitative performance indicators in 2Q15.

    By Gabriel Kane
  • uploads///Chart
    Macroeconomic Analysis

    PJP and PBE Are Sectoral Smart Beta Funds

    The PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP) is a smart beta fund that tracks the performance of the Dynamic Pharmaceutical Intellidex Index.

    By Ivan Kading
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.